Back
Frankfurt
WeeklyBUY
Long termAVOID
AJI.
AJI.F
AJINOMOTO CO. INC. R

Latest update

$25.10

Updated: Apr 28, 2026, 10:04 AM UTC

Browsing public data

Metrics

Loading fundamentals

Pulling sales, cash, and growth data for AJI.F.

Thesis

Why this read

This is a tactical timing call, not a broad fundamental endorsement. The technical structure—weekly trend, pullback to daily 21 EMA, tight consolidation—meets strategy setup criteria for a MARKUP continuation play. However, the extreme P/E (likely distorted by one-time items or data issue), evaporating volume, and proximity to 52-week highs with earnings in 10 days make this a lower-confidence, shorter-term position. Fundamentals are mixed: decent margins and cash flow but debt-heavy (D/E 68.6) and modest revenue growth.

Short-term thesis

Mixed28% conviction-30 ptsv1
Size small or stay away

The risk sleeve is too fragile to support aggressive exposure.

Long-term exposure

Avoid

The business or valuation backdrop is not ready for long-term conviction.

Entry window

Wait

The setup is fighting relative strength, so patience still matters.

Risk check

Fragile

The downside can widen quickly if this setup goes wrong.

Alignment

Mixed

Neither horizon fully wins, so size and patience matter.

What supports it

  • Sales and cash still support a long hold.
  • Price still looks reasonable against the business.
  • Share count has been shrinking instead of diluting holders.
  • The setup is leaning on a pullback entry near support.

What limits it

  • This needs smaller size or more patience.
  • Balance sheet is carrying real pressure.
  • Debt service looks stretched for current cash generation.
  • The stock is lagging the broad market by 9.7 points over the past month.

Long-term thesis

AJI.F (Ajinomoto) is the global leader in amino acid production, positioned to capture surging demand for alternative proteins, fermentation-based food ingredients, and biosolutions that replace petrochemical-derived products as food systems and supply chains decarbonize.

62opportunity
Crossing Chasm5y horizon

Demand Gap

Current global amino acid market ~$25B growing at 6-8% CAGR; Ajinomoto's biosolutions segment (enzymes, bio-based materials) is sub-$2B revenue but addressable market for bio-based chemicals exceeds $100B by 2030, with fermentation capacity buildout lagging demand by estimated 3-5 years

Dependency Chain

  1. 1If global food producers accelerate plant-based and precision-fermented protein adoption, demand for amino acid fortification and flavor modulation must grow
  2. 2If pharmaceutical and cosmetic industries shift from synthetic to bio-based ingredients, Ajinomoto's fermentation platform captures share
  3. 3If China and Southeast Asia continue protein consumption growth per capita, Ajinomoto's feed-grade amino acids (lysine, threonine) see volume expansion

Must be true

  • Ajinomoto maintains cost leadership in fermentation scale and yield against Chinese competitors expanding lysine/threonine capacity
  • Biosolutions segment achieves commercial scale in bio-based polymers and pharmaceutical intermediates beyond current pilot/demo plants

Thesis broken if

  • Chinese amino acid producers (Fufeng, Meihua) achieve sustained cost undercutting below Ajinomoto's marginal production cost for 2+ quarters
  • Biosolutions revenue growth drops below 10% annually for 18 months despite announced partnerships

History

Analysis timeline
1 runs

Jan 21, 1970

Latest

Updated Apr 28, 2026, 10:04 AM UTC

WeeklyBUY
Long termAVOID
Confidence58% · Medium

Price at review

$25.10

Price holds well above weekly 21 EMA with constructive daily consolidation near $24.50-25.00; volume collapse (-86%) into tight range suggests supply absorption before potential continuation. Near-term earnings risk in 10 days tempers conviction.